SCHEDULE 13D
Explanatory Note:
This joint statement on Schedule 13D/A (this “Statement”) is being filed late due to an administrative error.
Item 1. | Security and Issuer |
This Amendment No. 6 (“Amendment No. 6”) supplements and amends the Schedule 13D relating to shares of common stock, par value $0.0001 per share (the “Common Stock”), of RAPT Therapeutics, Inc., a Delaware corporation (the “Issuer”) that was filed with the Securities and Exchange Commission (the “SEC”) on November 8, 2019 as it was amended by Amendment No. 1 thereto filed with the SEC on February 14, 2020, Amendment No. 2 thereto filed with the SEC on August 26, 2020, Amendment No. 3 thereto filed with the SEC on October 1, 2020, Amendment No. 4 thereto filed with the SEC on August 30, 2021 and Amendment No. 5 thereto filed with the SEC on September 20, 2021 (collectively, the “Amended Statement”). Only those items that are reported are hereby amended; all other items reported in the Amended Statement remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Amended Statement. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.
Item 5. | Interest in Securities of the Issuer |
Solely on behalf of, and only to the extent that it relates to the Reporting Persons, Item 5 of the Amended Statement is hereby amended as follows:
(a) and (b) See Items 7-11 of the cover pages of this Amendment No. 6.
(c) On May 10, 2022, TCG IV LP purchased 1,208,750 Common Shares at a weighted average price per share of $10.6715 for aggregate purchase price of approximately $12,899,176.
On May 10, 2022, TCG IV-A LP purchased 41,250 Common Shares at a weighted average price per share of $10.6715 for aggregate purchase price of approximately $440,200.
On May 23, 2022, TCG IV LP purchased 9,898 Common Shares at a weighted average price per share of $12.4993 for aggregate purchase price of approximately $123,719.
On May 23, 2022, TCG IV-A LP purchased 338 Common Shares at a weighted average price per share of $12.4993 for aggregate purchase price of approximately $4,225.
On May 24, 2022, TCG IV LP purchased 15,776 Common Shares at a weighted average price per share of $12.0021 for aggregate purchase price of approximately $189,346.
On May 24, 2022, TCG IV-A LP purchased 538 Common Shares at a weighted average price per share of $12.0021 for aggregate purchase price of approximately $6,458.
On May 25, 2022, TCG IV LP purchased 1,837 Common Shares at a weighted average price per share of $12.4549 for aggregate purchase price of approximately $22,880.
On May 25, 2022, TCG IV-A LP purchased 63 Common Shares at a weighted average price per share of $12.4549 for aggregate purchase price of approximately $785.
(d) Under certain circumstances set forth in the respective limited partnership agreements of each of TCG II LP, TCG IV LP, TCG IV-A LP, Ponoi LP and Ponoi II LP (the “Funds”), the respective general partners and limited partners of the Funds may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.
(e) Not applicable.